Suggested remit: To appraise the clinical and cost effectiveness of abaloparatide within its marketing authorisation for treating idiopathic or hypogonadal osteoporosis in men.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 4059

Email enquiries


Key events during the development of the guidance:

Date Update
10 May 2023 The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
11 May 2022 - 10 June 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
11 May 2022 In progress. Scoping commenced
28 January 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual